These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 15654908)

  • 1. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
    Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
    Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
    Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.
    Kawatani T; Suou T; Tajima F; Ishiga K; Omura H; Endo A; Ohmura H; Ikuta Y; Idobe Y; Kawasaki H
    Eur J Haematol; 2001 Jul; 67(1):45-50. PubMed ID: 11553266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies.
    Said ZN; El-Sayed MH; El-Bishbishi IA; El-Fouhil DF; Abdel-Rheem SE; El-Abedin MZ; Salama II
    Liver Int; 2009 Apr; 29(4):518-24. PubMed ID: 19192168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
    Nakagawa M; Simizu Y; Suemura M; Sato B
    Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
    Yen TH; Huang CC; Lin HH; Huang JY; Tian YC; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
    Nephrol Dial Transplant; 2006 Apr; 21(4):1046-52. PubMed ID: 16390851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
    van der Eijk AA; Doorduijn JK; Janssen HL; Schalm SW; Niesters HG; de Man RA
    Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1140-4. PubMed ID: 12092307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.
    el-Sayed MH; Shanab G; Karim AM; el-Tawil A; Black A; Dixon JS
    Pediatr Hematol Oncol; 2004 Mar; 21(2):145-56. PubMed ID: 15160513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.
    Park SC; Jeong SH; Kim J; Han CJ; Kim YC; Choi KS; Cho JH; Lee M; Jung HH; Ki SS; Chang YH; Lee SS; Park YH; Lee KH
    J Med Virol; 2008 Jun; 80(6):960-6. PubMed ID: 18428141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy.
    Sekine R; Taketazu F; Kuroki M; Takagi S; Imawari M; Kanazawa Y; Kawakami M
    Int J Hematol; 2000 Apr; 71(3):256-8. PubMed ID: 10846831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
    Lalazar G; Rund D; Shouval D
    Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies.
    Ohtsu T; Sai T; Oka M; Sugai Y; Tobinai K
    Jpn J Clin Oncol; 1991 Oct; 21(5):360-5. PubMed ID: 1753416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
    Lim ST; Fei G; Quek R; Lim LC; Lee LH; Yap SP; Loong S; Tao M
    Eur J Haematol; 2007 Aug; 79(2):132-7. PubMed ID: 17635237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
    J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
    Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
    Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
    Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
    Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.